Rising Incidence of Coagulation Disorders Drives Heparin Market to Reach US$14.3 by 2023


Posted May 25, 2017 by hawerr

The global heparin market was valued at US$8.2 bn in 2014 and is estimated to reach US$14.3 bn by 2023 growing with 6.3% CAGR from 2015 to 2023.

 
Heparin is an injectable blood thinner, utilized for the treatment of deep vein thrombosis (DVT) and pulmonary embolism. It is also employed as part of the treatment of unstable angina and myocardial infarction. The increasing incidence of coagulation disorders is propelling the demand for heparin significantly across the world.

This 77 page report gives readers a comprehensive overview of the Heparin Market. Browse through 7 data tables and 16 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/heparin-market.html

The global heparin market has been analyzed on the basis of product in this research report. Ultra-low molecular weight heparin (ULMWHs), low molecular weight heparin (LMWHs), and unfractionated heparin are the major products available in the worldwide heparin market. ULMWHs has been the most commonly used heparin over the past decade. However, the increasing overall cost of ULMWHs is likely to hamper the growth of this market segment in the near future, states the research report.

The report also studies the global heparin market on the basis of its regional spread. According to the study, Europe, North America, Asia Pacific, and the Rest of the World are the prime regional markets for heparin.

Europe dominated the global heparin market in 2014, while North America occupied the second position. The rising incidence of coagulation disorders in North America and Europe is driving these regional markets significantly.

In addition to this, the growing prevalence of deep vein thrombosis (DVT), spurred by the rapid increase in the geriatric population, leading to cancer, heart failure, and obesity is likely to drive the demand for heparin in these regions over the forecast period, notes the research study.

The heparin markets in Asia Pacific and the Rest of the World are also expected to exhibit healthy growth during the forecast period on account of the presence of a largely untapped market. Analysts at TMR anticipate the economic growth, the infrastructural development in the healthcare sector, and the rising number of surgical procedures in these regions to fuel the demand for heparin significantly in the coming years.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Heparin Market by 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=803

Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, Fresenius Kabi AG, Mylan N.V., Sanofi S.A., Pfizer Inc., and Syntex S.A. are some of the key participants in the global heparin market profiled in the report.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Transparency Market Research
Country United States
Categories Health , Medical , News
Tags heparin market
Last Updated May 25, 2017